Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV)  
FLUZONE® HIGH-DOSE QUADRIVALENT  Supplier: Sanofi Pasteur

INDICATIONS:
- Individuals 65 years of age and older living in long-term care, assisted living facilities and First Nations communities.  

The vaccine is not approved for use in those under 65 years of age.

DOSES AND SCHEDULE:
- 1 dose given as 0.7 mL IM.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES AND RE-IMMUNIZATION:
Annually.

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of any type of influenza vaccine or to any component of FLUZONE® HIGH-DOSE QUADRIVALENT.
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a previous dose of influenza vaccine without another cause being identified.

PRODUCT COMPONENTS:
Potential allergens: ovalbumin.
Other components: formaldehyde, sodium phosphate-buffered isotonic sodium chloride solution, octylphenol ethoxylate (Triton® X-100).

PRECAUTIONS:
Severe oculo-respiratory syndrome (ORS) after a previous dose of influenza vaccine.  

SPECIAL CONSIDERATIONS:
Egg allergic individuals (including those who have experienced anaphylaxis following egg ingestion) can be immunized with inactivated or live attenuated influenza vaccine in any setting attended by immunization service providers who are following standard vaccine administration practice.  

---

A In the event of a surplus of FLUZONE® HIGH DOSE QUADRIVALENT in the provider’s publicly-funded inventory beyond that required for the intended populations, the vaccine may be provided to other individuals 65 years of age and older as part of the publicly-funded program in BC.

B See Safety Issues Applicable to Influenza Vaccines, 2. Oculo-Respiratory Syndrome (ORS).

Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV)  
**FLUZONE® HIGH-DOSE QUADRIVALENT**  Supplier: Sanofi Pasteur

ADVERSE EVENTS ^:  
Local: pain, redness, swelling, induration, bruising.  
**Systemic:** myalgia, headache, malaise, shivering. Fewer than 1 in 20 people may develop oculo-respiratory syndrome (ORS). Symptoms include red eyes, a cough, and/or sore throat and/or hoarseness.

---

^ These occur at similar frequencies among recipients of other influenza vaccines, are of short duration and rarely interfere with activities of daily living.